Merck wins FDA approval for Welireg+Keytruda in adjuvant clear cell kidney cancer, after study showed a 28% risk reduction vs. Keytruda alone.
June 12, 2026 04:52 PM EDT
FDA approves Merck's Welireg-Keytruda combo as adjuvant treatment for kidney cancer
Merck’s Welireg and Keytruda combination won approval as an adjuvant treatment for kidney cancer patients after surgery to remove all or …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
Merck & Co.’s first-in-class HIF-2 alpha inhibitor Welireg is touching down in the clear cell renal cell carcinoma (ccRCC) | The…
Belzutifan and pembrolizumab together reduced the risk of disease recurrence or death
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG®…
The FDA approved belzutifan with pembrolizumab as an adjuvant treatment for adults with clear cell renal cell carcinoma and a…
The F.D.A. approved Merck’s injected version of its blockbuster infusion Keytruda. The company says it will be quicker and…
Gilead And Merck Report Phase 3 HIV Trial Success As Separate Lung Cancer Study Of Trodelvy-Keytruda Combination Ends
Merck's Welireg-Keytruda pairing sticks the landing in adjuvant kidney cancer treatment with new FDA nod
Adjuvant Combination for Kidney Cancer Gets FDA's Blessing
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)
FDA approves belzutifan with pembrolizumab as adjuvant for renal cell carcinoma
Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial - Gilead Sciences (NASDAQ:GILD), Merck & Co (NYS
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer
FDA Approves Prostate Cancer Combo That Warranted Advisory Meeting
